Drugs / REC-1245
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06678659 | Nov 2024 → Oct 2028 expected | lymphoma, metastatic malignant neoplasm | Recursion Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REC-1245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06678659 ↗ |
| Route | Oral | “REC-1245 administered orally on a once daily (QD) schedule” NCT06678659 ↗ |